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Multidisciplinary treatment of advanced thymic neuroendocrine
carcinoma (carcinoid): Report of a successful case and review of the
literature
Pier Luigi Filosso, MD,a Guglielmo Maria Actis Dato, MD,b Enrico Ruffini, MD,a Sergio Bretti, MD,c Franca Ozzello, MD,d
and Maurizio Mancuso, MD,a Torino, Italy
Thymic carcinoid (TC) is a rare entity: since the firstdescription by Rosai and Higa1 in 1972, approximately150 cases have been reported in the literature. Thesetumors are frequently associated with endocrinopathies
(Cushing syndrome or multiple endocrine neoplasia type 1;
MEN-1) and carry a poor prognosis.2,3 TCs present an aggressive
biological behavior with a tendency to invade adjacent structures
(mediastinal fatty tissue, lung, pericardium, and great vessels) and
with a tendency for local recurrences or distant hematogenous
metastases.
Surgery, when feasible, represents the treatment of choice3-5
even if, in some cases, radical resection is not achieved. The role
of neoadjuvant or adjuvant therapy has not yet been assessed. We
describe the successful multidisciplinary management of a giant
TC treated with neoadjuvant radiotherapy/chemotherapy, radical
surgical resection, and preoperative, intraoperative, and postoper-
ative therapy with a somatostatin analog. In addition, we provide
a review of the recent literature about the management of these
tumors.
Clinical Summary
A 39-year-old man underwent a bioptic left anterior mediastinot-
omy for a large mediastinal mass, discovered after he presented
with cough and dyspnea. Histology revealed grade 2 neuroendo-
crine carcinoma (atypical carcinoid) of the thymus. Neoplastic
tissue strongly expressed somatostatin receptors (sst2), and chro-
mogranin immunostaining was positive. Total body computed
tomographic (CT) scan showed involvement of the anterior medi-
astinum, of the thoracic inlet, and of the left lung (Figure 1). No
distant metastases were seen. Indium 111 diethylenetriamine pen-
taacetic acid pentetreotide scintigraphy (Octreoscan; Mallincrodt
Medical BV, Zaltbommel, The Netherlands) confirmed an elective
uptake only in correspondence of the tumor (Figure 2).
Serum chromogranin A and neural specific enolase (NSE)
levels were 143.3 ng/mL (reference range, 20-100 ng/mL) and 83
ng/mL (reference value,  12.5 ng/mL), respectively. The pa-
tient’s clinical status was good, and no associate diseases were
evident.
Neoadjuvant chemotherapy/radiotherapy was started—4
courses of cisplatin (100 mg/m2 on day 1) and etoposide (100
mg/m2 on days 1-3 and 5) repeated every 3 weeks—followed by
irradiation (42 Gy in 2-Gy daily fractions) with a 10-MeV linear
accelerator. Because of the presence of sst2 in the biopsy speci-
men, Octreotide (Sandostatina Novartis Pharma, Milan, Italy) was
administered at 1500 mg/d subcutaneously for 15 days, shifting to
the long-acting form (20 mg every 28 days; Sandostatina LAR
Novartis Pharma, Milan, Italy).
Radiologic and radionuclide restaging (CT scan, magnetic res-
onance imaging, and Octreoscan) showed a moderate reduction of
the mediastinal lesion (Figure 3), without evidence of distant
metastases. Blood chromogranin A and NSE levels were 109 and
20.7 ng/mL, respectively. Surgery was thus planned.
To prevent the occurrence of refractory hypotension caused by
the release of vasoactive peptides during surgical manipulation of
the tumor, 100 mg of Octreotide was administered subcutaneously
before the operation and continuously at 50 mg/h intravenously
during surgery. Femoral vessels were prepared in case cardiopul-
monary bypass was needed.
A left lateral cervicotomy (medial to sternocleidomastoid mus-
cle) and a median sternotomy were performed. The tumor was
easily dissected free from the right hemithorax, but the involve-
ment of the thoracic inlet necessitated the resection of the left
brachiocephalic vein and some centimeters of the subclavian and
internal jugular veins.
A large tract of the involved pericardium, from the superior
vena cava to the left hilum, was resected, but no heart infiltration
was observed (Figure 4). The left main pulmonary artery was
involved by the tumor, and left pneumonectomy was necessary. A
transverse left sternotomy prolonged in an anterior thoracotomy in
the fourth intercostal space was performed, and en bloc resection
of the mediastinum along with the left lung was performed (Figure
5). Sampling mediastinal lymphadenectomy was performed. A
Prolene mesh (Ethicon, Inc, Somerville, NJ) was used to close the
large pericardial defect.
The procedure and the postoperative course were uneventful.
The patient was extubated 18 hours after the operation, transferred
to the ward on postoperative day 3, and discharged from the
hospital in good clinical condition on postoperative day 14.
Definitive histology showed a T2 N2 grade 2 neuroendocrine
carcinoma (atypical carcinoid) of the thymus with mediastinal
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lymph nodal metastases and invasion of the lung. The surgical
margins were tumor free.
Because of the radicality of the intervention, oncologists de-
cided that adjuvant chemotherapy or radiotherapy was not indi-
cated and put the patient under hormonal therapy with long-acting
Octreotide (20 mg). Follow-up was scheduled with blood marker
tests (chromogranin A and NSE) every 3 months and total body
CT scan and Octreoscan every 6 months.
At the 18-month follow-up, the patient was in good clinical
condition and had returned to his previous job (brick layer). Total
body CT scan and Octreoscan showed an absence of local recur-
rence or distant metastases. Serum chromogranin A and NSE
levels were 33 ng/mL (reference range, 20-100 ng/mL) and 9.2
ng/mL (reference value, 12.5 ng/mL), respectively. Medical
therapy was well tolerated, and no important side effects were
reported.
Comment
TC is a distinct clinicopathologic entity that has been confused
with thymoma since Rosai and Higa1 first described this tumor as
a separate entity in 1972. TC represents only 4% of all anterior
mediastinal tumors6 and is a rare entity: no more than 150 cases
have been described in the literature.
TCs are 3 times more frequent in men than in women4,7; tumors
have been described in patients from 8 years8 to 87 years old,9 but
more frequently they occur between the fourth and the sixth
decades of life. Most TCs present an aggressive biological behav-
ior from the time of presentation. Symptoms are usually strictly
related to the neoplastic mass effects: chest pain, cough, and
dyspnea are frequently observed. Superior vena cava syndrome is
described in approximately 20% of cases.3 A clinically apparent
endocrinopathy develops in approximately half of patients: Cush-
ing syndrome is the most frequent of these. de Perrot and associ-
ates10 reported that approximately 40 TCs associated with Cushing
syndrome had been described in the literature since 1972 and that
there was no difference in sex distribution in cases of TC and
Cushing syndrome.
TC can occur in association with other endocrine neoplasms
(eg, MEN-1), as Rosai and Higa11 first described in 1972. Since
then, the association between TC and MEN-1 has been recognized
Figure 1. CT scan of a giant invasive thymic carcinoid.
Figure 2. Octreoscan shows an elective uptake only in corre-
spondence with the thoracic lesion: no other pathologic images
are evident.
Figure 3. Preoperative thoracic magnetic resonance image (after
the neoadjuvant treatment).
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in several cases: Teh and associates2 concluded that approximately
20% of patients with TC presented with MEN-1. Patients with TC
and MEN-1 are predominantly men and tend to be younger than
those without any endocrine disease.
The aggressive biological behavior is in contrast with that of
generally benign carcinoids that arise elsewhere in the body, in
particular, bronchial carcinoid (BC). In our recently published
series,12 we observed lymph node metastases in only 6 (8%) of 75
typical BCs and in 14 (36%) of 38 atypical ones. The 10- and
15-year survival was 93% and 84% for typical BC and 52% and
52% for atypical BC, respectively.
TCs often present as locally invasive at the time of diagno-
sis7,13; Wang and colleagues14 described locally invasive TC in 7
of 8 patients. In the series of Fukai and colleagues,4 12 of 15 TCs
had invasive features.
Metastatic spread occurs by the hematogenous and lymphatic
route, as with thymic carcinomas. Mediastinal lymph node metas-
tases are frequently observed at presentation: de Montpre´ville and
associates3 and Fukai and colleagues4 reported metastatic TC in 7
of 14 and 9 of 15 patients, respectively.
Distant metastasis sites include lung, bone, adrenal glands,
liver, and spleen, in order of frequency. Distant metastases are
observed in approximately 20% of patients with TC with a pro-
tracted clinical course.3
To simplify the nomenclature and make it more uniform, TCs
have been reclassified according to specific criteria (mitotic activ-
ity, presence of necrosis, and cytologic atypia) as grade 1 neuroen-
docrine carcinoma (previous typical carcinoid), grade 2 neuroen-
docrine carcinoma (previous atypical carcinoid), and grade 3
neuroendocrine carcinoma (previously large-cell neuroendocrine
carcinoma and small-cell carcinoma).15,16 Histologic criteria of
this classification are shown in Table 1. In Table 2, a proposed new
TNM classification is shown.4
Most TCs are atypical carcinoids (or grade 2 neuroendocrine
carcinoma) because of an increased mitotic count, nuclear pleo-
morphism, and the presence of necrosis. Immunohistochemical
staining is usually strongly positive with chromogranin A and
synaptophysin; this is a useful tool for a correct diagnosis of
neuroendocrine carcinoma. Adrenocorticotrophic hormone stain-
ing is usually (but not necessarily) positive for TC associated with
Cushing syndrome.
Incomplete resections are frequent. In this case, the local re-
currence rate is high and survival is poor. Incomplete resections
and local recurrences are the factors that influence the outcome in
TC.3,17 de Montpre´ville and associates,3 on the basis of follow-up
of 13 patients, observed that the median survival for complete
resections (n 4), incomplete resections (n 5), and biopsy alone
(n  4) was 71, 30, and 5 months, respectively.
Surgery, when feasible, is the treatment of choice. An aggres-
sive approach often includes en-bloc resection of the tumor with
the pericardium, lung, great vessels, or all of these.18 Median
sternotomy is often indicated as a surgical approach, but occasion-
ally, in case of large and invasive TC, the addition of an anterior
(or posterolateral) thoracotomy should be considered to obtain
better exposure of the involved hemithorax.
Sampling lymphadenectomy is mandatory for staging and on-
cologic planning. Economopoulos and colleagues7 and Fukai and
associates4 concluded that long-term survival in TC can be
achieved only by resection of both the primary tumor and the
subsequent recurrences and metastases. Sakuragi and colleagues5
reported a successful radical resection of a recurrent TC in which
cardiopulmonary bypass was used to control the massive bleeding
caused by dense adhesions between the sternum and the great
vessels due to 3 previous interventions (2 sternotomies and 1
lateral thoracotomy).
Figure 4. Operative view of the large thymic tumor: the pericar-
dium is largely opened, but no heart infiltration is evident.
Figure 5. Surgical specimen of the radically resected thymic
carcinoid.













Necrosis Absent Present Present
Pleomorphism Minimal Moderate Moderate
Nuclear molding None Minimal Prominent
Crush artifact None Minimal Prominent
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The role of neoadjuvant/adjuvant therapy (chemotherapy or
radiotherapy alone or in combination) has not been adequately
assessed because of the low number of cases. Fukai and associates4
and de Perrot and colleagues10 reported the utility of postoperative
radiotherapy to prevent local recurrences of invasive TC; 45 to 60
Gy were administered. Sakuragi and colleagues5 reported that 1
patient who underwent 4 interventions received 39 Gy of adjuvant
radiotherapy after the third operation. Spaggiari and Pastorino18
reported use of adjuvant radiotherapy in a patient they operated on
for an invasive atypical TC; this patient was free of disease 10
months after the intervention.
There are no standard regimens of chemotherapy, and only
occasional experiences have been reported in the literature. Spag-
giari and Pastorino18 reported that their patient received 3 cycles of
neoadjuvant chemotherapy with ifosfamide and etoposide, but no
signs of response were observed. Single agents or combination
drug therapies with 5-fluorouracil, streptozocin, etoposide, or cis-
platin have been proposed by Wang and colleagues14 and
Takayama and colleagues19: these had no significant effect on
survival or recurrence rates. Gal and colleagues17 concluded that
neither chemotherapy nor radiotherapy leads to differences in
survival.
Our patient was a moderate responder to neoadjuvant chemo-
therapy/radiotherapy. This was enough to consider him for surgery
and to start hormonal therapy with Octreotide. To our knowledge,
this is the first case of successful multidisciplinary treatment of a
TC with neoadjuvant chemoradiotherapy, radical resection, and
hormonal therapy.
Neuroendocrine tumors, including thymic tumors, express sst2
at immunohistochemistry. In vivo sst2 expression is provided by
indium 111 diethylenetriamine pentaacetic acid pentetreotide scin-
tigraphy (Octreoscan).20,21
Recent generations of somatostatin analogs (Octreotide and
lanreotide) bind with high affinity to sst2 receptors22,23; Octreotide
has demonstrated good antiproliferative activity on neuroendo-
crine tumors, even if they are metastatic, without important side
effects.24 Serum chromogranin A seems very useful for monitoring
the disease, both with regard to recurrences and the efficacy of the
Octreotide therapy. However, any suspicion of relapse has to be
confirmed with CT scan and Octreoscan.
In conclusion, primary neuroendocrine thymic carcinomas are
rare and aggressive tumors that are often characterized by local
invasive behavior. An aggressive surgical approach remains the
treatment of choice; preoperative chemotherapy/radiotherapy (cis-
platin, etoposide, and 45 Gy of irradiation) and Octreotide therapy
should improve the possibility of achieving a radical resection.
Postoperative radiotherapy has been proposed to prevent local
recurrences, with unpredictable results. Adjuvant therapy with
Octreotide should be considered because of the well-recognized
antiproliferative activity of this drug and its limited side effects.
Because the in vivo sst2 expression is provided by Octreoscan, this
procedure should be considered for follow-up along with CT scan.
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Endometriosis-related pneumothorax:
Clinicopathologic observations from a
newly diagnosed case
Marco Alifano, MD,a Alessandra Cancellieri, MD,b Adele Fornelli, MD,b
Rocco Trisolini, MD,c and Maurizio Boaron, MD,a Bologna, Italy
Pneumothorax related to thoracic endometriosis has beengenerally considered to be a rare entity.1 Exact causativeand pathogenic mechanisms are relatively poorly known,and controversies continue.2 Very recently, Alifano and
coworkers3 performed a prospective study on spontaneous pneu-
mothorax (SP) in women of reproductive age and found that
catamenial pneumothorax (CP), a typical manifestation of thoracic
endometriosis, accounted for 25% of all cases of SP referred for
surgical intervention. In that study all the patients with CP had
diaphragmatic abnormalities (nodules or holes), and endometriosis
was proved in all but one case. Treatment involved partial dia-
phragmatic resection, mechanical pleurodesis, and ovarian sup-
pression therapy.
In the present article the clinicopathologic findings of a newly
diagnosed case of endometriosis-related pneumothorax were stud-
ied to provide further insight into this condition.
Clinical Summary
A 39-year-old woman with an unremarkable clinical history was
hospitalized for dyspnea and right-sided chest pain. Chest radiog-
raphy revealed a complete right-sided pneumothorax. Tube thora-
costomy was performed, obtaining immediate lung re-expansion.
Drainage was discontinued on the third day, and the patient was
discharged. Because pneumothorax had occurred on the third day
of her menstrual cycle, CP was suspected, and therefore the patient
was seen at the outpatient clinic on the fourth day of the subse-
quent cycle. The results of clinical examination and chest radiog-
raphy were strictly normal. One week thereafter, mild exertional
dyspnea appeared. Chest radiography and thoracic computed to-
mographic scanning revealed a partial pneumothorax. The decision
to perform video-assisted thoracoscopy was made. At exploration,
both the lung and the parietal pleura were normal, and no pulmo-
nary air leak was identified at lung re-expansion with the cavity
filled with saline solution. Exploration of the diaphragm showed
multiple infracentimetric holes and brown-violet nodules, involv-
ing a 3 5–cm area of the tendinous portion of the muscle. On the
basis of these findings and in agreement with previous experience,3
conversion to video-assisted minithoracotomy was made, and a
partial diaphragmatic resection, including the pathologic area, was
carried out. The defect was repaired with interrupted nonabsorb-
able sutures. Pleural brushing was performed.
The postoperative course was uneventful, and control inspira-
tory and expiratory chest radiographs were fully satisfactory. A
6-month ovarian suppression therapy (triptorelin, 3.75 mg [De-
capeptyl; Ipsen Biotech, Paris, France], administered intramuscu-
larly once a month) was planned.
Grossly, the resected specimen was an extremely thin portion
of diaphragm with several infracentimetric holes and nodules
(Figure 1, A). In some areas the whole thickness of the diaphragm
was less than 80 m. At light microscopy, the diaphragm mainly
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